Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA ScFv-CD3 ScFv-Fc (tetravalent)
- Development stage
- Preclinical
- Lead developer
- ProMab Biotechnologies
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BCMA ScFv-CD3 ScFv-Fc (tetravalent) is a bispecific T-cell engager (BiTE) construct developed by ProMab Biotechnologies for the treatment of multiple myeloma. This specific molecular architecture utilizes a tetravalent format, incorporating humanized single-chain variable fragments (scFv) targeting B-cell maturation antigen (BCMA) and CD3, fused to an Fc region. The humanized BCMA component is derived from clone 4C8A. By simultaneously binding to BCMA on malignant plasma cells and CD3 on T cells, the antibody facilitates the formation of an immunological synapse, leading to T-cell activation and redirected cytotoxic lysis of the tumor cells. Preclinical studies presented at AACR 2022 demonstrated that this tetravalent design, along with other bispecific formats, exhibits high affinity for BCMA-positive cells and potent dose-dependent cytotoxicity in multiple myeloma cell lines (such as MM1S and H929) and xenograft mouse models.
- Other names
- tetravalent BCMA-CD3 bispecific antibodyhBCMA-CD3 tetravalent antibodyhBCMA-CD-3 tetravalent antibodyhBCMA-CD 3 tetravalent antibody
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on BCMA ScFv-CD3 ScFv-Fc (tetravalent).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA ScFv-CD3 ScFv-Fc (tetravalent).